Esperion's NEXLETOL reduced major adverse cardiovascular events by 23% in obese patients, per CLEAR Outcomes study.
Esperion presents new data from CLEAR Outcomes study, showing NEXLETOL reduced major adverse cardiovascular events by 23% in obese patients vs placebo. The study also highlights clinical benefits in women and Hispanic/Latinx patients with or without cardiovascular disease. CLEAR Outcomes sets new standards for diversity and inclusion with 48% female and 17% Hispanic/Latinx enrollees.
April 07, 2024
3 Articles